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Abstract
Antipsychotic-induced sexual dysfunction is a common and serious clinical side effect. It has been demonstrated that both
neuronal nitric oxide (nNOS) and dopamine D2 receptor (DRD2) in the medial preoptic area (MPOA) and the paraventricular
nucleus (PVN) of the hypothalamus have important roles in the regulation of sexual behaviour. We investigated the
influences of 21 days’ antipsychotic drug administration on expression of nNOS and DRD2 in the rat hypothalamus.
Haloperidol (0.5 mg/kg/day i.p.) significantly decreased nNOS integrated optical density in a sub-nucleus of the MPOA,
medial preoptic nucleus (MPN), and decreased the nNOS integrated optical density and cell density in another sub-nucleus
of the MPOA, anterodorsal preoptic nucleus (ADP). Risperidone (0.25 mg/kg) inhibited the nNOS integrated optical density
in the ADP. nNOS mRNA and protein in the MPOA but not the PVN was also significantly decreased by haloperidol.
Haloperidol and risperidone increased DRD2 mRNA and protein expression in both the MPOA and the PVN. Quetiapine
(20 mg/kg/day i.p.) did not influence the expression of nNOS and DRD2 in either the MPOA or the PVN. These findings
indicate that hypothalamic nNOS and DRD2 are affected to different extents by chronic administration of risperidone and
haloperidol, but are unaffected by quetiapine. These central effects might play a role in sexual dysfunction induced by
certain antipsychotic drugs.
Citation: Zhang XR, Wang YX, Zhang ZJ, Li L, Reynolds GP (2012) The Effect of Chronic Antipsychotic Drug on Hypothalamic Expression of Neural Nitric Oxide
Synthase and Dopamine D2 Receptor in the Male Rat. PLoS ONE 7(4): e33247. doi:10.1371/journal.pone.0033247
Editor: Xiang Yang Zhang, Baylor College of Medicine, United States of America
Received August 13, 2011; Accepted February 13, 2012; Published April 13, 2012
Copyright:  2012 Zhang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the National Basic Research Program of China (973 Program, 2010CB529602), National Natural Science Foundation of
China (No. 30900482 and F040805), and JiangSu Province Natural Science Foundation of China (BK2009280). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: zhijunzhang838@yahoo.com.cn
. These authors contributed equally to this work.
Introduction
Antipsychotic-induced sexual dysfunction is a common and
serious clinical side effect, which is gaining increasing attention
within the past decade. Sexual dysfunction has important
implications for satisfaction with sexual life and overall quality of
life [1,2]. It is one of the major reasons for treatment non-
compliance and inevitably affects overall clinical outcome and
treatment success [3,4,5].
The mechanism of antipsychotic drug-induced sexual dysfunc-
tion is complex and remains unclear. Generally, the sensory
information related to sexual behaviour is processed at various
brain nuclei, which balance the inhibitory and excitatory influence
on spinal sympathetic and parasympathetic centres, and then
determine the functional state of the sexual effector organ [6].
Antipsychotics might act both centrally and peripherally to induce
sexual dysfunction. We have shown that some antipsychotics
change NOS activity and expression in penile tissues [7], as well as
demonstrating functional effects on male sexual behaviour in the
rat [8,9]. Research directly investigating the central mechanisms of
antipsychotic-induced sexual dysfunction is particularly rare.
Understanding of these mechanisms is mostly theoretical, deriving
from general knowledge of sex physiology and psychopharmacol-
ogy, and is generally unverified by basic or clinical investigation.
The medial preoptic area (MPOA) and the paraventricular
nucleus (PVN) are two critical brain structures for male sexual
behaviour. These nuclei receive direct and indirect input from
every sensory modality and send projections to extra-hypothalamic
brain areas for the initiation and patterning of copulation [10,11].
The MPOA and PVN also have mutual connectivity [12,13].
Neuroanatomical studies further indicated that the MPOA could
be divided into several sub-regions, which have different roles in
the regulation of sexual function. Lesion studies have inferred that
the caudal MPOA could impair copulation more severely than the
rostral MPOA while the dorsal MPOA (anterodorsal preoptic
nucleus, ADP) may be more important than the medial and other
MPOA regions for copulatory behaviour [14,15].
Previous studies have indicated that dopamine and nitric oxide
(NO) might be two of the most important neuromodulators with
facilitative effects on sexual function in both the MPOA and the
PVN [16]. A direct dopamine D2 receptor antagonist effect has
been proposed as the primary underlying mechanism of sexual
dysfunction after antipsychotic drug administration [17]. Halo-
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impair sexual behaviour after acute microinjection into the
MPOA [18] and the PVN [11]. However, the role of dopamine
D2 antagonism has not been tested with other antipsychotic
drugs, notably the newer atypical drugs.
The importance of NO in sexual function has been demon-
strated by the observation that a NO precursor (L-arginine)
facilitates male sexual function, while a NOS inhibitor (L-
nitroarginine methyl ester, L-NAME) injected into either the
MPOA [10] or the PVN [19], reduces it. An early study suggested
that haloperidol could inhibit neuronal nitric oxide synthase
(NOS) activity by preventing electron transfer [20], while
apomorphine, a mixed D1/D2 agonist, increased NO production
in the PVN, which was correlated with penile erection. Acute
haloperidol (0.5 mg/kg i.p.) prevented apomorphine’s effect on
both NO2
2 concentration and penile erection [21]. Therefore, the
NO pathway might also be involved in the development of
antipsychotic-induced sexual dysfunction.
The current study investigated the expression of neural NOS
(nNOS) and the dopamine D2 receptor in the MPOA and PVN
after chronic systemic administration of the typical antipsychotic
haloperidol, and the atypical antipsychotics risperidone and
quetiapine, in which haloperidol and risperidone, but not
quetiapine are associated with a high incidence of sexual
dysfunction in both humans [22,23] and rats [9].
Methods
Animals
3-month-old male Sprague-Dawley rats (Shanghai Laboratory
Animal Centre, China) were used. After being quarantined for 1
week, animals were housed five or six to a cage with free access to
food and water, at an ambient temperature of 18–22uC and 60%
humidity with a 12-h light/dark cycle (lights on 7.00AM –
7.00PM). The animals were handled daily. All procedures in
animal experiments were approved by the Animal Study
Committee of Southeast University, China (ethics approval
number 2006ZDLL009.0).
Drug Administration and Experimental Design
Four groups of 3-month-old male Sprague-Dawley rats (n=7 in
each group) received intraperitoneal injection of haloperidol
(0.5 mg/kg), risperidone (0.25 mg/kg), quetiapine (20 mg/kg) or
vehicle (saline) once daily for 21 days. The haloperidol dose was
chosen to obtain effective receptor occupancy (Wadenberg et al,
2001); does for risperidone and quetiapine were chosen on the
basis of their relative clinical potency (Jibson and Tandon, 1998).
Risperidone (Sigma, Poole, UK), haloperidol (Seranace liquid,
2 mg/ml) and quetiapine (AstraZeneca, Macclesfield, UK) were
dissolved in a few drops of glacial acetic acid, diluted with distilled
water and buffered back with NaOH to pH 6.0. The vehicle was
saline previously acidified to pH 6.0. The experiment was
performed three times for immunocytochemistry, gene expression
and protein expression.
Immunohistochemistry of nNOS
At the end of the drug administration, the rats were sacrificed by
deep anaesthesia with 30 mg/kg pentobarbital i.p. followed by
transcardial perfusion with 4% paraformaldehyde (PFA) in 0.1 M
phosphate buffered saline (PBS). Brains were removed and fixed in
4% PFA for 4 days before being embedded in wax. Three sections
(7 mm) from MPOA between Bregma 20.30 and 20.40 mm,
determined using the rat brain stereotaxic atlas [24], were
mounted onto slides coated with 3-aminopropyltriethoxysilane
(APES) (Sigma). PVN sections were taken from Bregma 21.60 to
– 1.88 mm. Avidin-Biotin Complex (ABC) method was used to
stain for nNOS immunoreactivity. Briefly, following clearing in
xylene and rehydration in graded alcohol, sections were incubated
in hydrogen peroxide solution to inhibit endogenous peroxidase
activity and a microwave treatment protocol was employed to aid
antigen retrieval. Sections were then blocked with 10% normal
horse serum diluted in 0.01 M PBS. The sections were incubated
with a mouse anti-rat polyclonal primary antibody raised against
the C-terminal of nNOS protein (1095–1289) (Product NO
610308, BD Transduction Laboratories, USA) at a dilution of
1:6000 in antibody dilution buffer (10% normal serum in 0.01 M
PBS) overnight at 4uC, followed by incubation with biotinylated
secondary antibody (anti-mouse IgG) (Vector Laboratories,
Burlingame, CA) at a dilution of 1:200 for 2 h at room
temperature. Sections were then incubated for 2 h at room
temperature with ABC solution (Vectastain elite kit, Vector
Laboratories, Burlingame, CA) and peroxidase was stained by
incubation with 3,39-diaminobenzidine (DAB) solution containing
nickel chloride. No immunoreactivity could be detected in control
sections, in which the primary antibody was omitted from the
staining protocol.
The composite images containing total left and right MPOA
and PVN were captured using a RGB JVC solid-state camera
connected to an Olympus BH2 microscope at 10-fold objective
magnification fitted with a motorized stage. Then two immuno-
histochemical parameters, the neural positive cell density and
integrated optical density (IOD), were analysed using Image-pro
plus software (version 4.1, Diagnostic, Inc.) in three horizontal
sections (28 mm apart) in each structure. The quantification
processes were set blind to section code until the analysis was
finished. Two sub-nuclei, anterodorsal preoptic nucleus (ADP) and
medial preoptic nucleus (MPN), were investigated in the MPOA,
with ADP and MPN defined by a 0.2 6 0.3 mm
2 and 0.4 6
0.6 mm
2 rectangle area respectively [25]. The PVN field area was
defined by the area within its clear border after DAB staining.
Stained neurons were counted using a manual counting option,
and then calculated as neuronal density (cells/mm
2). Integrated
optical density (IOD) is the summation of total pixel optical density
in the sub-nuclei [26,27,28,29].
nNOS and DRD2 mRNA Measurement
Brains from each animal were immediately frozen in liquid
nitrogen and then allowed to thaw slightly on ice. The MPOA slice
was made by cutting between the anterior and posterior edges of
the optic chiasm. The tissue containing the MPOA was isolated by
cutting laterally to the lateral sulcus and to the depth of the
anterior commissure [30]. The PVN slice was made by cutting
rostral to the optic chiasm and again 2 mm posterior to the first
cut. The tissue containing the PVN was dissected out by cutting
1.5 mm lateral to the median line and undercutting at a depth of
3 mm [31]. The tissues were finally stored at 280uC until analysis.
Total RNA was isolated from the tissue after homogenization
using phenol- chloroform TRIzol (Sigma, USA). Genomic DNA
contaminants were removed by treatment of the tissue extract with
RNase-free DNase (Promega, USA). First-strand cDNA was then
synthesized from 2 mg total RNA by incubating with Oligo(dT)15
Primer and M-MLV Reverse Transcriptase according to the
manufacturer’s protocol (Promega, USA).
The expression level of nNOS and DRD2 mRNA was
examined by a quantitative real-time PCR method using an ABI
Prism 7000 Sequence Detector (Applied Biosystems, USA). b-actin
was used as the endogenous control. Rat-specific oligonucleotide
primers were designed and synthesized by Invitrogen (China) as
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TA-39, REV 59-GCG GTT GGT CAC TTC ATA CGT TC-39;
DRD2: FWD 59-AGA CGA TGA GCC GCA GAA AG -39, REV
59-GCA GCC AGC AGA TGA TGA AC-39; b-actin: FWD 59-
GGA GAT TAC TGC CCT GGC TCC TA-39, REV 59-GAC
TCA TCG TAC TCC TGC TTG CTG-39. A final 20 ml reaction
was prepared with 10 ml SYBR Green Premix Ex Taq (TaKaRa,
Japan), 0.4 ml ROX Reference Dye, 0.8 ml primer pairs, 6.8 ml
sterile water and 2 ml cDNA sample. Samples were analysed in
triplicate, while a negative control using water as template was
included for each primer pair. The PCR reaction was started with
an initial enzyme activation step at 95uC for 10 seconds followed
by 40 cycles of denaturation at 95uC for 5 seconds and annealing/
extension at 62uC for 34 seconds. Data were evaluated by the
relative quantification method with efficiency calibrated mathe-
matical model using the control group as a calibrator for
comparison of every unknown sample gene expression level [32].
The conversion between Ct and relative gene expression level is n
fold induction 2-Ct relative to b-actin.
Western Blotting Measurement of nNOS and DRD2
The isolated samples were homogenized in lysis buffer (contain-
ing 50 mM Tris-HCl, 150 mM NaCl, 0.02 NaN2, 1 mM PMSF,
1 mg/mL Aprotitin and 1% Triton X-100) in the presence of
protease inhibitors (5 mL/mL of protease inhibitor cocktail,
Sigma). After centrifugation (12,000g, 25 min, 4uC), protein
concentration of the supernatant was estimated by the method
of Bradford. About 50 mg total protein was then boiled in sample
buffer for 5 min and separated by SDS-PAGE using 10%
polyacrylamide gels. After electrophoresis, the proteins were
transferred to PVDF membranes (Millipore) for 120 min. The
membranes were treated with a blocking buffer (5% nonfat dry
milk with 0.1% Tween-20) and incubated with primary nNOS
and DRD2 antibody respectively (mouse monoclonal antibody
against nNOS 1:500, Transduction Laboratories, Lexington, KY;
Rabbit polyclonal antibody against DRD2 1:200, Chemicon
International Inc., Temecula, CA) at 4uC overnight. The blots
were incubated with a peroxidase-conjugated anti-mouse IgG
(Santa Cruz). The reactive bands were detected with an enhanced
chemiluminescence method (ECL; Amersham Biosciences). Quan-
titation of protein bands was carried out by optical densitometry.
b-tubulin was used as a control.
Statistical Analysis
Positive cell density, integrated optical density and mRNA
expression were expressed as mean 6 s.e.means and were analysed
by one-way ANOVA followed by post-hoc Dunnett’s t-test. p,0.05
was considered statistically significant.
Results
Immunohistochemistry of nNOS
nNOS positive cell density. The effects of antipsychotic
drugs on nNOS positive cell density in the MPOA and PVN are
shown in Figure 1. One-way ANOVA showed no significant effect
of antipsychotic drug on nNOS positive cell density after three
weeks’ administration in the MPN [F(3, 24)=0.081, p=0.970] but
revealed a significant between-groups effect on nNOS positive cell
density in ADP [F(3,24)=3.743, p=0.024]. Individual comparisons
with the vehicle group revealed that nNOS positive cell density in
the ADP was significantly reduced by haloperidol (p=0.033), but
not by risperidone (p=0.668) or quetiapine (p=0.997). No
significant effect of antipsychotic drug on nNOS positive cell
density was found in the PVN [F(3, 24)=0.812, p=0.500].
Integrated optical density of nNOS staining. The effects
of antipsychotic drugs on nNOS integrated optical density (IOD)
in the MPOA and PVN are shown in Figure 1. One-way ANOVA
revealed a significant between groups effect in the MPN
[F(3,24)=3.125, p=0.045]. Individual comparisons with the
vehicle group revealed that IOD of nNOS staining was
significantly reduced by three weeks’ administration of
haloperidol (p=0.015), but not by risperidone (p=0.212) or
quetiapine (p=0.320). A significant effect was also seen in the ADP
[F(3, 24)=4.016, p=0.019]. Individual comparisons with vehicle
group revealed that IOD of nNOS staining in the ADP was
significantly reduced by three weeks administration of haloperidol
(p=0.038) and risperidone (p=0.049), but not by quetiapine
(p=0.989). No significant effect of antipsychotic drug on IOD was
found between groups in the PVN [F(3, 24)=1.089, p=0.373].
Relative Gene Expression of nNOS and DRD2
nNOS. The effects of antipsychotic drugs on nNOS mRNA
expression in the MPOA and PVN are shown in Figure 2. One-
way ANOVA revealed a significant effect of antipsychotic
administration on nNOS mRNA expression [F(3,24)=4.213,
p=0.016] in the MPOA. Individual comparisons with the
vehicle group revealed that nNOS mRNA expression in the
MPOA was significantly reduced by administration of haloperidol
(p=0.006) but not by risperidone (p=0.374) and quetiapine
(p=0.644). No significant effect of antipsychotic drug on nNOS
mRNA expression was found between groups in the PVN [F(3,
24)=1.089, p=0.373].
DRD2. The effects of antipsychotic drugs on DRD2 mRNA
expression in the MPOA and the PVN were shown in Figure 3.
One-way ANOVA revealed a significant effect of antipsychotic
administration on DRD2 mRNA expression [F(3,24)=23.691,
p,0.001] in the MPOA. Individual comparisons with vehicle
group revealed that DRD2 mRNA expression in the MPOA was
significantly increased by three weeks administration of
haloperidol (p,0.001) and risperidone (p=0.001), but not by
quetiapine (p=0.929).
One-way ANOVA also revealed a significant effect of
antipsychotic administration on DRD2 mRNA expression
[F(3,24)=6.947, p=0.002] in the PVN. Individual comparisons
with vehicle group revealed that DRD2 mRNA expression in the
PVN was significantly increased by administration of haloperidol
(p=0.001) and risperidone (p=0.013), but not by quetiapine
(p=0.412).
Protein Expression of nNOS and DRD2
nNOS. The nNOS monomers display sizes corresponding to
approximately 155 kDa, whileb-tubulin has a size of
approximately 55 kDa. One-way ANOVA revealed a significant
effect of antipsychotic administration on nNOS expression in the
MPOA [F(3,24)=18.115, p,0.001] but not the PVN
[F(3,24)=0.027, p=0.994]. Individual comparisons with vehicle
group revealed that nNOS protein expression in the MPOA was
significantly decreased by administration of haloperidol (p,0.001)
but not risperidone (p=0.999) or quetiapine (p=0.619) (Figure 4).
DRD2. The DRD2 immunoreactivity identified a protein
band corresponding to approximately 48 kDa. One-way ANOVA
revealed a significant effect of antipsychotic administration on
DRD2 expression in both the MPOA [F(3,24)=13.976, p,0.001]
and the PVN [F(3,24)=30.737, p,0.001]. Individual comparisons
with vehicle group showed that DRD2 protein expression was
significantly decreased by administration of haloperidol (MPOA:
p,0.001; PVN: p=0.01) and risperidone (MPOA: p,0.001;
PVN: p=0.002) but not quetiapine (p.0.05) (Figure 4).
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The present study evaluated a possible relationship between
chronic antipsychotic drug administration and the expression of
nNOS in regions of the hypothalamus implicated in sexual
function. nNOS catalyzes the synthesis of neuronal NO from L-
arginine. Behavioural and neurochemical studies indicate that
neuronal NO plays a key role in the central mechanism of
sexual function. Originally nNOS was considered a constitutively
expressed enzyme but accumulating evidence demonstrates that
nNOS expression is highly susceptible to regulation by various
physiological or pathological conditions [33]. Previous studies
Figure 1. Immunohistochemistry of nNOS in the MPOA and PVN following three weeks of antipsychotic drug administration. nNOS
immunostaining in the MPOA (A) and the PVN (D); Quantitative analyses of nNOS positive cell density in the MPOA (B) and the PVN (E), Haloperidol
significantly decreased the nNOS positive cell density in the ADP; Quantitative analyses of nNOS IOD in the MPOA (C) and the PVN (F). Haloperidol
significantly decreased nNOS IOD in MPN and ADP, and risperidone inhibited the nNOS IOD in the ADP. 3 v: third ventricle; ac: anterior commissure;
ADP: anterodorsal preoptic nucleus; ox: optic chiasma; IOD: integrated optical density; MPN: medial preoptic nucleus. Scale bar:200 mm. *p,0.05 vs
Vehicle.
doi:10.1371/journal.pone.0033247.g001
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antipsychotic medication, while the reported effects varied
widely with different antipsychotic drugs and different brain
regions (as summarised in [7]). Our current study is consistent
with those previous findings in that haloperidol and risperidone,
but not quetiapine, decreased immunopositive neuron density
and IOD of nNOS in the ADP and the MPN to different
extents.
Along with the inhibitory effect of haloperidol on nNOS
immunoreactivity, chronic treatment with haloperidol decreased
levels of nNOS mRNA and protein in the MPOA. These findings
indicate that haloperidol might suppress nNOS gene transcription
and protein expression, which then reduces the production of
neuronal NO in the MPOA and finally lead to sexual dysfunction.
The mechanism underlying down-regulation of nNOS synthesis
following haloperidol administration remains unclear. nNOS is
regulated by Ca
2+ influx through L-type voltage-sensitive Ca
2+
channels [33], while haloperidol has been demonstrated to inhibit
the L-type Ca
2+ channel at micromolar concentrations [34]. Wu
et al., (2000) reported that haloperidol but not risperidone (both
10 uM) could significantly reduce the amplitude of L-type Ca
2+
current in vitro [35]. Collectively, these studies provide a possible
mechanism underlying the effect of haloperidol on nNOS
expression. However, these inhibitory effects occurred at relatively
high concentrations, and extrapolation to the in vivo situation
should be undertaken with caution.
Risperidone also showed an effect on nNOS expression in the
MPOA, indicated by a suppression of nNOS IOD in the ADP,
although nNOS-immunopositive neuron density was not signifi-
cantly changed. Risperidone did not significantly influence nNOS
mRNA and protein levels in the MPOA; however differences
restricted to individual sub-nuclei may not be detectable in this
analysis as they may not be robust enough to influence the result in
the whole nucleus.
In the hypothalamus, dopamine D2 receptor density is rich in
both the MPOA and the PVN [36,37]. Sexual function was
noticeably inhibited after infusions of haloperidol to the MPOA or
the PVN [11,18]. D2 receptor expression in the brain is increased
after chronic treatment with antipsychotic drugs [38,39], while
continuous infusion of the dopamine D2 agonist quinpirole can
cause a significant down-regulation of striatal D2 dopamine
receptors [40]. The alterations of D2 receptor expression also
parallel dopamine-mediated behaviours, such as stereotypy and
locomotor behaviour [40]. Although the increase in D2 receptors
is not always accompanied by an increase in D2 mRNA [41],
higher doses and more prolonged exposure to antipsychotic drugs
do elevate D2 mRNA [42,43]. We find that haloperidol and
risperidone increased the DRD2 mRNA and protein expression in
the MPOA and the PVN. This is the first study providing direct
evidence for dopamine D2 receptor alteration induced by
antipsychotic drugs in those two neural sites. Our study also
provides strong support for the hypothalamic dopamine D2
receptor antagonism hypothesis of antipsychotic drug-induced
sexual dysfunction. This hypothesis is also supported by our
previous observation of an association of D2 receptor polymorph-
isms with sexual dysfunction in male subjects receiving antipsy-
chotic treatment [44].
While the current study is limited by using only single dose
regimes, these were chosen to be equivalent to clinically-effective
doses on the basis of inducing substantial and effective dopamine
Figure 2. Expression of nNOS mRNA in the MPOA (A) and the
PVN (B) following three weeks of antipsychotic drug adminis-
tration. nNOS mRNA in the MPOA but not the PVN was significantly
decreased by haloperidol. Data were relative to b-actin mRNA.
*p,0.05 vs Vehicle.
doi:10.1371/journal.pone.0033247.g002
Figure 3. Expression of DRD2 mRNA in the MPOA (A) and the
PVN (B) following three weeks of antipsychotic drug adminis-
tration. Haloperidol and risperidone increased DRD2 mRNA expression
in both the MPOA and the PVN. Data were relative to b-actin mRNA.
*p,0.05 vs Vehicle.
doi:10.1371/journal.pone.0033247.g003
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investigated the effects of a range of doses of these three drugs in
rat sexual behavior; the doses chosen here were at (haloperidol) or
below (risperidone and quetiapine) the threshold dose that
impaired aspects of male sexual function [9].
As reviewed by Hull and Dominguez [10], chemosensory
information activates the MPOA neurons, resulting in Ca
2+ influx
and NOS activation. The resultant NO production may increase
dopamine neurotransmission to facilitate sexual function via D2-
like receptors. The incerto-hypothalamic dopaminergic neuron
terminals from the MPOA release dopamine in the PVN and then
activate NOS production in the oxytocin-containing neurons of
the PVN, which in turn facilitates penile erection [11,19].
According to our current findings, antipsychotic drugs might
impair sexual function through the following various mechanisms:
1) down-regulation of nNOS expression, thereby decreasing
production of NO and consequently synaptic dopamine in the
MPOA and/or 2) blocking the postsynaptic D2 receptor directly
in the PVN and consequently inhibiting sexual behaviour. These
central effects might be involved in sexual dysfunction induced by
certain antipsychotic drugs. These differences of sexual dysfunc-
tion induced by various antipsychotic drugs observed in clinical
medication are likely because of the different pharmacological
properties of these antipsychotics.
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